Venture Visionary Partners LLC Sells 75,877 Shares of Novo Nordisk A/S $NVO

Venture Visionary Partners LLC cut its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 94.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,732 shares of the company’s stock after selling 75,877 shares during the quarter. Venture Visionary Partners LLC’s holdings in Novo Nordisk A/S were worth $263,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Lockheed Martin Investment Management Co. lifted its holdings in Novo Nordisk A/S by 179.4% in the second quarter. Lockheed Martin Investment Management Co. now owns 43,450 shares of the company’s stock valued at $2,999,000 after buying an additional 27,900 shares during the period. Martin Capital Partners LLC raised its position in shares of Novo Nordisk A/S by 53.8% in the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock worth $6,524,000 after acquiring an additional 41,129 shares in the last quarter. Acadian Asset Management LLC lifted its stake in shares of Novo Nordisk A/S by 15,919.9% in the 1st quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company’s stock valued at $72,523,000 after purchasing an additional 1,038,137 shares during the period. Unified Investment Management bought a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at about $692,000. Finally, Guild Investment Management Inc. grew its stake in Novo Nordisk A/S by 20.7% during the second quarter. Guild Investment Management Inc. now owns 36,995 shares of the company’s stock worth $2,553,000 after purchasing an additional 6,345 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Wednesday, December 3rd. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $50.00 to $46.00 and set a “market perform” rating for the company in a research note on Tuesday, November 25th. Berenberg Bank raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Wednesday, September 17th. Jefferies Financial Group assumed coverage on shares of Novo Nordisk A/S in a research note on Monday, October 27th. They issued an “underperform” rating for the company. Finally, The Goldman Sachs Group cut their price objective on shares of Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating on the stock in a research report on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, eleven have given a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $53.33.

Novo Nordisk A/S Trading Down 0.3%

NVO opened at $47.61 on Friday. Novo Nordisk A/S has a fifty-two week low of $43.08 and a fifty-two week high of $104.75. The firm has a market capitalization of $212.59 billion, a PE ratio of 13.84 and a beta of 0.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. The company’s 50-day moving average is $50.01 and its 200 day moving average is $57.86.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The firm had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. As a group, research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.